TriNetX, a Cambridge, Mass.-based global health research network, raised $40m in Series D financing.
The round, which brought total funding to $102m, was led by Merck Global Health Innovation Fund (Merck GHIF) along with new investors Mitsui & Co., Ltd., ITOCHU Technology Ventures, ITOCHU Corporation, and existing investors MPM Capital, F2 Ventures, and Deerfield Management.
The company intends to use the funds to accelerate its ongoing international expansion efforts in Europe, Asia and South America, to further develop its analytics platform, especially in the areas of artificial intelligence, machine learning and digital clinical trials.
Led by Gadi Lachman, CEO, TriNetX enables researchers to apply a data-driven approach to clinical trial design, site selection and the generation of RWE by providing web-based, on-demand access to harmonized clinical and claims data with a suite of intuitive analytics. The global clinical and claims data representing over 300 million patients available through TriNetX is mapped to controlled terminology and consists of clinical facts from hundreds of healthcare organizations, deep specialty data across all therapeutic areas, and linked medical claims, pharmacy claims and EMR data.
Since TriNetX began commercialization, its customer base has expanded to include 29 industry customers, consisting of nine of the top 15 pharmaceutical companies including Novartis, Sanofi and Pfizer, and five of the top contract research organizations (CROs).
The platform is powered by a network of healthcare organizations across 17 countries, including the US, UK, Germany, Italy, Japan, Singapore, India and Brazil.